Stories

Read about interesting projects coming out of Stanford Biodesign and the remarkable people who make them happen.

  • Beaming Health: When Passion and Need Align

    When Marissa Pittard and Chris Olmanson were assigned to the same class project team in the Biodesign for Digital Health course, they initially had no idea that their shared commitment to helping families and children with special needs would lead them to launch a company in the space. But just a few years later, Beaming Health is helping tens of thousands of families access the services and support they need to help their children thrive.

  • Improving Mental Health by Letting Psychiatrists Focus on their Patients

    With Osmind, Stanford Biodesign student Lucia Huang and her co-founder Jimmy Qian used need-driven innovation principles to create an electronic health records system that allows psychiatrists to provide better treatment to individual patients while also collecting real-world data to advance the state of care more broadly.

  • From Need to Reimbursed Technology: Lessons from an 11-Year Journey

    After completing the Biodesign Innovation course, Miles Rosen and Steve Herbowy set out to address the unmet need of fecal incontinence. Little did they know, it would take 11 years to develop their technology and pave the way for its widespread adoption. Reimbursement proved to be a particularly challenging hurdle on the path to market. In this story, Rosen shares lessons learned on the journey to securing reimbursement coverage.

  • Managing Diabetes in Pregnancy with a Digital App

    Monitoring blood sugar levels and sharing the data with care providers can be overwhelming. Malama makes it easier.

  • From the Innovator's Workbench with Anne Wojcicki

    As a featured speaker in the Stanford Biodesign From the Innovator’s Workbench series, Wojcicki told the story of her groundbreaking company, 23andMe —from its origin through her decision to take the company public with a special-purpose acquisition company (SPAC) that raised nearly $600 million. Read the story here.

  • Stanford Biodesign Policy Survey Finds Multi-Year Delays in Access to Breakthrough Medical Devices

    New research from the Health Technology Innovation Policy Program at the Stanford Byers Center for Biodesign quantifies the delays in Medicare coverage of breakthrough technologies and the benefits of an accelerated pathway in encouraging invention and investment in areas of critically important unmet clinical needs.

  • Singapore Biodesign: Eleven Years of Growth Culminates in Prestigious Affiliate Status

    Over 11 years, Singapore Biodesign has grown from a single class of fellows to a robust capability initiative that has met the rigorous criteria needed to be awarded affiliate status.

  • An Innovative Partnership

    "As surgeons we tend to be very needs-oriented. We see a problem and we want to fix it." Learn how the longstanding collaboration between Stanford Biodesign and the Department of Otolaryngology is generating solutions to compelling problems like high frequency hearing loss, pediatric ear disease, and more.

  • DxD Event Showcases the Power of Mentoring for Women

    After an industry survey found that women with mentors scored significantly higher on questions around job satisfaction and an inclusive environment than women without, DxD HealthTech launched a series of virtual speed mentoring events to bring early and mid-career women together with senior industry executives for a fast-paced 90 minutes of career advice and networking.

  • Helping Define the Future of Healthcare in Israel

    2016-17 Stanford Biodesign Innovation Fellow Leor Perl is working to advance the innovation ecosystem in Israel on several fronts. As an interventional cardiologist, he uses his patient experience to inspire ideas to improve care. He launched an innovation training hub inside his hospital that is moving multiple projects towards the market. And he’s putting his training to work each day as CMO of a health technology start-up that recently completed its first-in-human trials.